Ace Integrative Health Stem Cell Investigation

Written by 
Published on:
November 16, 2026
Updated on:
November 16, 2026

The Lyon Firm is examining marketing materials associated with Ace Integrative Health, an R3-affiliated clinic, to better understand how stem cell and regenerative medicine treatments have been presented to prospective patients.

The marketing of stem cell treatments offered through affiliated clinics in Ohio and California is receiving renewed scrutiny following an August 14, 2026, warning letter from the U.S. Food and Drug Administration (FDA) to R3 Medical Companies.

Ace Integrative Health operates as an affiliate of the R3 Stem Cell network, which connects participating clinics with R3's regenerative medicine products, treatment programs and marketing infrastructure. This affiliation provides relevant context for reviewing the representations patients may have encountered when considering treatment.

The FDA's warning letter to R3 identifies several products distributed through R3's network, including ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB. According to the agency, these products were marketed for potential benefits involving inflammation, joint pain, neurological conditions and other medical problems.

The FDA concluded that the products were unapproved new drugs and unlicensed biological products. It also identified significant manufacturing violations involving the facilities responsible for producing and distributing the products.

FDA Warning Letter to R3

R3's business model makes the relationship with participating clinics particularly relevant. The company's own description of its R3 Alliance program promotes a turnkey arrangement that provides participating medical practices with marketing, patient lead generation, consultations, scheduling assistance and provider training. The company describes the program as a way for existing practices to establish regenerative medicine services through the R3 network.

The Lyon Firm's investigation is not alleging any wrongdoing, and is based only on publicly available marketing materials associated with Ace Integrative Health, including representations about stem cell treatments, exosome products, advertised benefits and the information provided to prospective patients.

An important question is whether consumers received sufficiently clear information about the products being administered, their regulatory status and the scientific evidence supporting advertised benefits.

The FDA's warning letter was directed to R3 Medical Companies, not Ace Integrative Health. It does not establish that Ace violated any law or that its individual providers engaged in misconduct. The investigation is intended to examine the relationship between the businesses in Ohio and California and determine whether any consumer-protection concerns warrant further legal review.

The Lyon Firm Is Investigating Stem Cell Marketing Claims

Consumers who purchased stem cell or exosome treatments after seeing advertising about potential medical benefits may have questions about the representations made to them.

The Lyon Firm and its attorneys are pursuing stem cell fraud claims involving potentially misleading treatment marketing. Patients who received treatment through Ace Integrative Health or another R3-affiliated clinic are encouraged to contact the firm to discuss their experiences and potential legal options.

Contact Us

Request a Free Consultation

Taking the first step doesn’t have to be complicated. In just a few minutes, you can share the basics of your case, and our team will guide you from there:

  • It begins with a few simple questions about your situation.
  • From there, a member of our legal team reviews your case.
  • Together, we’ll chart the path forward, helping you take the next step toward resolution.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.